Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study of Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ Metastatic Triple Negative Breast Cancer (mTNBC)

NCT03838367 is registered in ClinicalTrials.gov with CytoDyn, Inc. as lead sponsor.

NCT NCT03838367
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03838367 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study of Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ Metastatic Triple Negative Breast Cancer (mTNBC)
Lead sponsor
CytoDyn, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
April 22, 2019
Completion date
September 16, 2022
Enrollment
10 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

triple negative breast neoplasms